The Johnson & Johnson COVID-19 vaccine could be a two-dose regimen if it proves to provide more protection than one, a White House adviser said Thursday.
“Johnson & Johnson is currently evaluating how their vaccine will perform with two measures – in other words, their own increase,” said Andy Slavitt, senior consultant to the COVID response team. 19, he said in an interview on Washington Post Live.
“Pending those results, awaiting what the FDA has to say if the vaccine is approved in the first place, there may be a second view of Johnson & Johnson.”
The vendor announced a large-scale trial to test the two-dose regimen in November.
The company said it planned to enroll as many as 60,000 participants worldwide for the study, which was run in parallel with a one-dose trial.
Participants receive either a placebo or the experimental picture, currently called Ad26COV2, followed by another dose or placebo 57 days later.
“The study will evaluate the effectiveness of the vaccine vaccinated after both the first and second doses to assess the protection against the virus and potential increased benefits for the duration of protection with a second dose. , ”Said J&J in a statement.
The company has already filed for emergency approval of the single-dose COVID-19 vaccine, which has been shown to be 66 percent effective against moderate to severe cases.
If adopted by the Food and Drug Administration, it must go face-to-face with two-dose competitors Pfizer and Moderna, both of which offer efficiencies greater than 90 percent.
With post wires